The Centre for Medicines Discovery aims to catalyse the discovery and development of new medicines for patients.
26 February 2021
The Kessler group describes a new methodology named ABPP-HT (high-throughput-compatible activity-based protein profiling), implementing a semi-automated proteomic workflow to profile a panel of deubiquitylating enzyme (DUB) inhibitors in cells. This allows direct cellular target engagement of small molecules against cellular DUBs, thereby accelerating DUB drug discovery.
23 February 2021
The Bullock Lab at CMD Oxford were delighted to be a part of this review from LUMC Leiden on Fibrodysplasia ossificans progressiva; an ultrarare congenital disease that progresses through intermittent episodes of bone formation at ectopic sites.
Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease
12 February 2021
Neuroinflammation collaboration targeting inflammasome steps-up-the-pace in race for Alzheimer’s disease medicines that alleviate the burden of devastating disease.
In collaboration with the Midwood group @KirOxford, the @YueLabOX & @bmarsden19 labs at @CmdOxford have developed a Target Enabling Package for Tenascin-C, a protein upregulated at sites of #inflammation & contributing to #autoimmune diseases #TNC #TEPs http://doi.org/10.5281/zenodo.4429107
Inflammasome activation controlled by the interplay between post-translational modifications: emerging drug target opportunities.
Liang Z. et al, (2021), Cell Commun Signal, 19
TP-MAP - an Integrated Software Package for the Analysis of 1D and 2D Thermal Profiling Data
Feyertag F. and Huber KVM., (2021)
Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva
Ventura F. et al, (2021), Biomedicines, 9, 213 - 213